Since its inception in 1984, the TIMI Study Group has been an Academic Research Organization dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease. We have led a wide array of trials, from phase I to phase IV, enrolling from less than 30 to more than 26,000 subjects, and with both industry and NIH support. Trials have been conducted in over 50 countries and at more than 5000 separate sites.

We investigate a broad array of therapeutic interventions in individuals across the spectrum of cardiovascular disease, ranging from prevention in those with risk factors, to emergent interventions in those with acute manifestations of disease. In addition, we have used our large database of clinical findings, biomarkers, and genotypes to enhance the understanding of cardiovascular disease and its risk factors.

By leading large-scale, international, randomized controlled trials of novel therapeutics and performing sophisticated analyses, we have been privileged to help shape the very practice of cardiovascular medicine for over a quarter of a century.

Therapeutics

TIMI Study Group

Sabatine

Andrea Bellavia

Julia F. Kuder

Erica L. Goodrich

Jianping Guo

Estella Kanevsky

Yared Gurmu

Sabina A. Murphy

Rose Hamershock

Minao Tang

Jing Zhou

Francesco Nordio

The Biostatistics Team at TIMI Study Group plays a crucial role in designing, analyzing, and interpreting data from clinical trials focused on cardiovascular disease. They employ advanced statistical methodologies to ensure rigorous evaluation of therapeutic interventions, contributing to the generation of evidence that shapes clinical practice. Collaborating closely with clinical and research teams, they translate complex data into actionable insights, enhancing the understanding of cardiovascular health and risk factors.

Biostatistics Team

Clinical Research Team

Biostatistics Team

About

Team members

Other teams at TIMI Study Group

Clinical Research Team